CA2622242A1 - Inhibition de l'expression genique virale a l'aide d'un petit arn interferent - Google Patents

Inhibition de l'expression genique virale a l'aide d'un petit arn interferent Download PDF

Info

Publication number
CA2622242A1
CA2622242A1 CA002622242A CA2622242A CA2622242A1 CA 2622242 A1 CA2622242 A1 CA 2622242A1 CA 002622242 A CA002622242 A CA 002622242A CA 2622242 A CA2622242 A CA 2622242A CA 2622242 A1 CA2622242 A1 CA 2622242A1
Authority
CA
Canada
Prior art keywords
seq
sequence
shrna
rna
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002622242A
Other languages
English (en)
Inventor
Roger L. Kaspar
Heini Ilves
Attila A. Seyhan
Alexander V. Vlassov
Brian H. Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somagenics Inc
Original Assignee
Somagenics Inc.
Roger L. Kaspar
Heini Ilves
Attila A. Seyhan
Alexander V. Vlassov
Brian H. Johnston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/032768 external-priority patent/WO2006031901A2/fr
Application filed by Somagenics Inc., Roger L. Kaspar, Heini Ilves, Attila A. Seyhan, Alexander V. Vlassov, Brian H. Johnston filed Critical Somagenics Inc.
Publication of CA2622242A1 publication Critical patent/CA2622242A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
CA002622242A 2005-09-12 2006-06-01 Inhibition de l'expression genique virale a l'aide d'un petit arn interferent Abandoned CA2622242A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2005/032768 WO2006031901A2 (fr) 2004-09-10 2005-09-12 Petits arn interferents inhibant efficacement l'expression genique virale et methodes d'utilisation associees
USPCT/US2005/032768 2005-09-12
PCT/US2006/021253 WO2007032794A2 (fr) 2005-09-12 2006-06-01 Inhibition de l'expression genique virale a l'aide d'un petit arn interferent

Publications (1)

Publication Number Publication Date
CA2622242A1 true CA2622242A1 (fr) 2007-03-22

Family

ID=37708176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002622242A Abandoned CA2622242A1 (fr) 2005-09-12 2006-06-01 Inhibition de l'expression genique virale a l'aide d'un petit arn interferent

Country Status (9)

Country Link
EP (1) EP1979480A2 (fr)
JP (1) JP2009521207A (fr)
KR (1) KR20090003147A (fr)
CN (2) CN101305095B (fr)
AU (1) AU2006291568A1 (fr)
BR (1) BRPI0615717A2 (fr)
CA (1) CA2622242A1 (fr)
RU (1) RU2008114304A (fr)
WO (1) WO2007032794A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042115A2 (fr) * 2007-09-24 2009-04-02 Rosetta Inpharmatics Llc Procédés de mise au point d'arn en épingle à cheveux courts (arnsh) pour le silençage de gènes
ES2708944T3 (es) * 2008-09-22 2019-04-12 Dicerna Pharmaceuticals Inc Composiciones y métodos para la inhibición específica de la expresión de genes por DSRNA que tenga modificaciones
JP2012505657A (ja) 2008-10-15 2012-03-08 ソマジェニックス インク． 遺伝子発現の阻害のためのショートヘアピンｒｎａ
CA3151965A1 (fr) * 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Agents allonges servant de substrats de dicer et procedes d'inhibition specifique de l'expression d'un gene
EP2454371B1 (fr) 2009-07-13 2021-01-20 Somagenics, Inc. Modification chimique de petits arn en épingle à cheveux pour l'inhibition d'une expression de gène
KR102072631B1 (ko) * 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
KR101668954B1 (ko) 2015-05-29 2016-10-24 연세대학교 산학협력단 ＨＣＶ ＩＲＥＳ를 표적으로 하는 Ｃ형 간염 바이러스 치료제 siRNA
CA3046504A1 (fr) 2016-12-15 2018-06-21 Meharry Medical College Agents antiviraux
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
MX2021001056A (es) 2018-08-13 2021-04-12 Alnylam Pharmaceuticals Inc Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1430157B1 (fr) * 2002-02-20 2011-08-10 Sirna Therapeutics, Inc. Inhibition de l'expression du gene du virus de l'hepatite c (vhc) induite par l'interference d'arn au moyen d'acide nucleique interferant court (sina)
JP2008512500A (ja) * 2004-09-10 2008-04-24 ソマジェニックス インコーポレーティッド ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法
CN100344331C (zh) * 2004-09-22 2007-10-24 广州拓谱基因技术有限公司 用于预防或治疗丙型肝炎的靶向小干扰rna制剂及其制备方法

Also Published As

Publication number Publication date
AU2006291568A1 (en) 2007-03-22
JP2009521207A (ja) 2009-06-04
CN102827841A (zh) 2012-12-19
KR20090003147A (ko) 2009-01-09
EP1979480A2 (fr) 2008-10-15
WO2007032794A2 (fr) 2007-03-22
BRPI0615717A2 (pt) 2011-05-24
CN101305095B (zh) 2012-09-26
WO2007032794A3 (fr) 2007-08-30
RU2008114304A (ru) 2009-11-20
CN101305095A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
US7902351B2 (en) Inhibition of viral gene expression using small interfering RNA
CA2622242A1 (fr) Inhibition de l'expression genique virale a l'aide d'un petit arn interferent
Kronke et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs
Kanda et al. Small Interfering RNA Targeted to Hepatitis C Virus 5′ NontranslatedRegion Exerts Potent Antiviral Effect
AU2005240118C1 (en) Methods and compositions for reducing viral genome amounts in a target cell
Chen et al. Inhibition of hepatitis B virus replication by stably expressed shRNA
EP2316942B1 (fr) Sequences vhb et vhc conservees utilisees pour un silençage genique
Vlassov et al. shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA
Sim et al. RNA interference against enterovirus 71 infection
Chevalier et al. Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs
Watanabe et al. Therapeutic application of RNA interference for hepatitis C virus
Li et al. In vitro inhibition of CSFV replication by multiple siRNA expression
Yi et al. Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells
Jarczak et al. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons
Kim et al. Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model
Zekri et al. Consensus siRNA for inhibition of HCV genotype-4 replication
KR100733186B1 (ko) Ｈｃｖ 유전자에 특이적인 작은 간섭 ｒｎａ 및 그를유효성분으로 포함하는 ｃ형 간염 치료제
Wilson et al. Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV
Qin et al. siRNAs targeting terminal sequences of the SARS-associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA
MX2008003504A (en) Inhibition of viral gene expression using small interfering rna
Shier et al. Effect of RNA interference on the hepatitis C virus core expression in HepG2/C3A cells using genotype 4 isolates from Saudi patients
US20090203890A1 (en) Hepatitis c antivirals
Ding et al. Stably silencing of CD81 expression by small interfering RNAs targeting 3'-NTR inhibits HCV infection
Scott Inhibition of Rift Valley Fever Virus Using RNA Interference Technology
Rotterdam Chapter Title Gene Therapies for Hepatitis C Virus Copyright Year 2015 Copyright Holder American Society of Gene and Cell Therapy Corresponding Author Family Name Verstegen Particle

Legal Events

Date Code Title Description
FZDE Discontinued